Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artemisia sieversiana pollen allergen extract is a standardized sublingual immunotherapy (SLIT) solution used for the treatment of seasonal allergic rhinitis, allergic conjunctivitis, and allergic asthma triggered by Artemisia (mugwort) pollen. Developed and manufactured by Zhejiang Wolwo Bio-pharmaceutical under the brand name Aishu, it is the first Artemisia-specific SLIT product approved in China. The therapy works by inducing immune tolerance through the sublingual administration of increasing doses of the allergen. This process modulates the immune system by shifting the T-cell response from a pro-allergic Th2 profile to a regulatory Th1/Treg profile, characterized by increased production of IL-10 and TGF-beta, a reduction in allergen-specific IgE levels, and an increase in protective IgG4 antibodies. It is particularly effective for patients in Northern and Western China, where Artemisia pollen is a major seasonal allergen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on artemisia sieversiana pollen allergen extract.